Shockwave Therapy for Plantar Fasciitis

What Is Plantar Fasciitis?

You wake up, swing your feet to the floor, and the first step sends a sharp, stabbing pain through your heel. You limp to the bathroom, and after a few minutes the pain dulls to a deep ache. By afternoon it flares again. This has been your morning routine for months — maybe longer. If this sounds familiar, you are likely dealing with plantar fasciitis, and you are far from alone.

Plantar fasciitis is the most common cause of heel pain in adults, affecting roughly two million Americans each year. The condition involves degeneration and micro-tearing of the plantar fascia, a thick band of connective tissue that runs along the bottom of the foot from the heel bone (calcaneus) to the base of the toes. Despite its name suggesting inflammation (“-itis”), chronic plantar fasciitis is now understood to be primarily a degenerative process — sometimes called plantar fasciosis — where the tissue fails to heal properly.

Most cases respond to conservative treatments like stretching, orthotics, physical therapy, and rest within six to twelve months. But for roughly 10-20% of patients, the pain persists despite months of these interventions. This is where shockwave therapy enters the picture as an FDA-cleared, non-surgical option that targets the underlying tissue degeneration rather than simply masking pain.

How Shockwave Therapy Works for Plantar Fasciitis

Extracorporeal shockwave therapy (ESWT) delivers focused acoustic energy pulses through the skin to the damaged plantar fascia at its attachment point on the heel. Unlike ultrasound, which uses continuous low-energy waves, shockwave therapy uses high-amplitude pressure pulses that create a controlled micro-trauma at the tissue level.

This mechanical stimulus triggers several biological responses that promote healing. First, it stimulates neovascularization — the formation of new blood vessels — in the chronically degenerated tissue, improving oxygen and nutrient delivery to an area with notoriously poor blood supply. Second, shockwave energy disrupts pain-signaling nerve fibers (nociceptors) in the area, providing an analgesic effect that can begin shortly after treatment.

At the cellular level, research indicates that shockwave therapy upregulates growth factors including vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS), both critical for tissue repair. It also appears to stimulate tenocyte (tendon cell) proliferation and collagen synthesis, essentially restarting the healing process in tissue that had stalled in a cycle of failed repair.

Two types of shockwave are used for plantar fasciitis. Focused shockwave (fESWT) delivers energy to a precise depth and is the modality used in most FDA-clearance studies. Radial shockwave (rESWT) disperses energy over a broader area from the skin surface and is more widely available in outpatient clinics. Both have demonstrated effectiveness, though they differ in protocol and intensity. For a deeper comparison, see our guide on focused vs. radial shockwave therapy.

What the Research Says

Plantar fasciitis has the strongest evidence base of any condition treated with shockwave therapy, and it is the indication for which ESWT first received FDA clearance in the United States.

Gerdesmeyer et al., 2008 (American Journal of Sports Medicine): This multicenter, randomized controlled trial compared focused ESWT to placebo in 250 patients with chronic plantar fasciitis that had persisted for at least six months despite conservative treatment. At 12 weeks, the shockwave group showed significantly greater improvement in pain (measured by Visual Analog Scale) and function (Roles and Maudsley score) compared to placebo. The success rate was 61.0% in the ESWT group versus 42.2% in the sham group. Benefits were maintained at 12-month follow-up, suggesting durable results.

Rompe et al., 2010 (American Journal of Sports Medicine): Rompe and colleagues compared low-energy radial shockwave therapy to plantar fascia-specific stretching in 102 patients with chronic plantar fasciitis. At the 24-month follow-up, both groups showed significant improvement, but the shockwave group demonstrated superior outcomes on several measures. This study is particularly notable because it showed rESWT was more effective than an active, evidence-based comparator — not just a sham.

Wang et al. (Journal of Bone and Joint Surgery): Wang’s research demonstrated that ESWT produced significant improvement in pain and functional outcomes compared to conservative treatment in patients with recalcitrant plantar fasciitis. Ultrasonographic evaluation showed reductions in plantar fascia thickness and resolution of hypoechoic changes, suggesting actual structural healing rather than just pain relief.

FDA Clearance Context: The OssaTron device received FDA 510(k) clearance in 2000 based on a pivotal trial showing that 47% of ESWT patients achieved treatment success (defined as 50% or greater reduction in pain) compared to 30% in the placebo group. While these numbers may seem modest, they represent patients who had already failed all other non-surgical treatments for six months or more.

A 2017 meta-analysis published in the Journal of Orthopaedic Surgery and Research pooled data from nine randomized controlled trials and concluded that ESWT provides significantly better pain relief than placebo for chronic plantar fasciitis, with the greatest benefit seen in patients who had failed conservative treatment for at least six months.

What to Expect During Treatment

A typical shockwave session for plantar fasciitis takes 15 to 20 minutes from start to finish. Here is what the process looks like.

Your provider will start by examining your foot to identify the point of maximum tenderness, which is usually at or near the medial calcaneal tubercle — the inside front edge of the heel bone where the plantar fascia attaches. This is the primary treatment target.

You will be seated or lying face-down with your foot accessible. The provider applies ultrasound gel to the heel area and positions the shockwave applicator directly over the tender zone. Treatment begins at a low energy level and gradually increases to a therapeutic intensity based on your tolerance.

During the session, you will feel a repetitive tapping or pulsing sensation. The intensity ranges from mildly uncomfortable to moderately painful, especially directly over the most inflamed area. Most providers deliver between 2,000 and 3,000 impulses per session for radial shockwave, or 1,500 to 2,500 for focused shockwave. Some clinics offer local anesthesia, though research suggests that treating without anesthesia may produce better outcomes — the pain response appears to play a role in the biological healing mechanism.

After the session, you can walk immediately and resume normal daily activities. Most providers recommend avoiding high-impact exercise (running, jumping) for 48 to 72 hours after each session.

Number of Sessions & Recovery Timeline

The number of sessions depends on the type of shockwave used and the severity of your condition.

Radial shockwave (rESWT): The most common protocol involves three to five sessions, spaced one week apart. Each session lasts about 15 minutes. This is the modality available in most outpatient orthopedic, podiatry, and sports medicine clinics.

Focused shockwave (fESWT): Protocols typically involve one to three sessions at higher energy levels, spaced one to two weeks apart. Sessions may be slightly shorter but more intense.

Recovery timeline:

• Weeks 1-2: Some patients experience temporary soreness or mild bruising at the treatment site. A small subset may feel increased heel pain in the first few days — this is a normal inflammatory response and generally resolves quickly.
• Weeks 2-4: Many patients begin to notice reduced morning pain and improved function.
• Weeks 4-12: Progressive improvement continues as the biological healing response matures. New blood vessel formation and collagen remodeling are ongoing processes.
• 3-6 months: Maximum benefit is typically reached. Most clinical studies assess final outcomes at the three-month mark.

It is important to understand that shockwave therapy is not a quick fix — it initiates a healing process that unfolds over weeks to months. Patients who combine shockwave with eccentric stretching and appropriate footwear tend to report the best outcomes.

Cost & Insurance Coverage

Shockwave therapy for plantar fasciitis typically costs between $300 and $600 per session, with a full course of treatment (three to five sessions) ranging from $900 to $3,000 depending on your location, the type of shockwave used, and the provider’s practice setting.

Insurance coverage: Because ESWT has FDA clearance for chronic plantar fasciitis, some insurance plans cover it — but coverage is inconsistent. Medicare has a national non-coverage determination for ESWT, though some Medicare Advantage plans may cover it. Private insurers vary widely. Many require documentation that you have failed at least six months of conservative treatment before they will authorize coverage.

What to ask your insurer:

• Is extracorporeal shockwave therapy (CPT codes 0101T, 0102T, or 28890) covered under my plan?
• Is prior authorization required?
• Do I need documentation of failed conservative treatment, and if so, for how long?

Many patients pay out of pocket, and some providers offer package pricing for a full course of treatment that reduces the per-session cost. Given that the alternative for recalcitrant plantar fasciitis is often surgery (plantar fasciotomy), which carries its own costs and a multi-week recovery period, shockwave therapy can represent a cost-effective option. For a broader look at pricing, see our shockwave therapy cost guide.

Who Is a Good Candidate?

Shockwave therapy for plantar fasciitis works best for a specific patient profile. You may be a good candidate if:

• You have had heel pain for six months or longer
• You have tried and failed at least two conservative treatments (stretching, orthotics, physical therapy, corticosteroid injections, night splints)
• Your pain is localized to the plantar fascia insertion on the heel
• You want to avoid surgery or have been told surgery is the next step

Conditions that may reduce effectiveness:

• Acute plantar fasciitis (less than six weeks) — conservative treatments should be tried first
• Pain caused primarily by other conditions (tarsal tunnel syndrome, fat pad atrophy, stress fractures)
• Patients who cannot tolerate the discomfort of treatment

Contraindications — shockwave therapy should NOT be used if you have:

• A bleeding disorder or are taking anticoagulant medication (blood thinners)
• An active infection at the treatment site
• A tumor or malignancy in the treatment area
• Pregnancy (treatment near the uterus is contraindicated; heel treatment is generally considered low risk, but discuss with your provider)
• Severe peripheral neuropathy that prevents accurate pain feedback during treatment

If you have been dealing with chronic heel pain that will not quit, shockwave therapy is one of the most studied non-surgical options available. Talk with a qualified provider to find out whether it is appropriate for your situation.

Learn More

Explore our complete guide to shockwave therapy conditions or browse our latest research and articles to learn more about ESWT treatment options.

References

1. Gerdesmeyer L, Frey C, Vester J, et al. Radial extracorporeal shock wave therapy is safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. Am J Sports Med. 2008;36(11):2100-2109. PubMed

2. Rompe JD, Cacchio A, Weil L Jr, et al. Plantar fascia-specific stretching versus radial shock-wave therapy as initial treatment of plantar fasciopathy. J Bone Joint Surg Am. 2010;92(15):2514-2522. PubMed

3. Wang CJ, Wang FS, Yang KD, et al. Long-term results of extracorporeal shockwave treatment for plantar fasciitis. Am J Sports Med. 2006;34(4):592-596. PubMed

4. Sun J, Gao F, Wang Y, Sun W, Jiang B, Li Z. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. J Orthop Surg Res. 2017;12(1):78.